Xenon Pharmaceuticals Inc. - Common Stock (XENE)

Historical Holders from Q4 2014 to Q3 2025

Symbol
XENE on Nasdaq
CUSIP
98420N105
Type / Class
Equity / Common Stock
Shares outstanding
77.3M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
84.3M
Holdings value
$3.39B
% of all portfolios
0.006%
Grand Portfolio weight change
+0%
Number of holders
213
Number of buys
97
Number of sells
-90
Average Value change %
+0%
Average buys %
+0.002%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Xenon Pharmaceuticals Inc. - Common Stock (XENE)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 11.5% +12% $316M $34.9M 8.82M +12.4% FMR LLC Jun 30, 2025
BlackRock, Inc. 6.2% $171M 4.76M BlackRock, Inc. Jun 30, 2025
JANUS HENDERSON GROUP PLC 5.1% $158M 3.94M JANUS HENDERSON GROUP PLC Sep 30, 2025
WELLINGTON MANAGEMENT GROUP LLP 2.8% $68.1M 2.17M Wellington Management Group LLP Jun 30, 2025

Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 84.3M $3.39B +$52.6M $40.15 213
2025 Q2 83.1M $2.6B +$191M $31.30 205
2025 Q1 76.7M $2.58B +$10.2M $33.55 206
2024 Q4 76.3M $2.99B +$30M $39.20 208
2024 Q3 74.9M $2.95B +$110K $39.37 203
2024 Q2 74.2M $2.89B +$26.5M $38.99 211
2024 Q1 73.5M $3.16B +$59.1M $43.05 219
2023 Q4 139K $6.41M +$1.7M $46.06 3
2023 Q3 61.3M $2.09B +$2.76M $34.16 178
2023 Q2 61.3M $2.36B +$10.3M $38.50 171
2023 Q1 61.1M $2.18B +$26.6M $35.79 159
2022 Q4 60.4M $2.38B +$39.3M $39.43 155
2022 Q3 56.7M $2.05B +$60.2M $36.10 147
2022 Q2 57M $1.73B +$241M $30.42 148
2022 Q1 49M $1.5B +$45M $30.57 126
2021 Q4 47.7M $1.49B +$452M $31.24 128
2021 Q3 34.1M $521M +$394K $15.28 115
2021 Q2 33.3M $620M +$2.29M $18.62 98
2021 Q1 32.9M $590M +$88.7M $17.90 88
2020 Q4 28M $430M -$1.91M $15.38 78
2020 Q3 27.9M $309M -$546K $11.07 79
2020 Q2 28M $351M +$8.43M $12.54 77
2020 Q1 27.7M $314M +$101M $11.34 69
2019 Q4 18.7M $245M +$22.9M $13.11 65
2019 Q3 16.1M $145M -$14.7M $9.01 52
2019 Q2 17.6M $173M -$1.93M $9.86 57
2019 Q1 17.7M $180M +$3.71M $10.16 60
2018 Q4 17.5M $110M -$23.3M $6.31 56
2018 Q3 17.7M $233M +$114M $13.20 59
2018 Q2 9.02M $83M +$29.1M $9.20 40
2018 Q1 6.34M $31.1M -$13.8M $4.90 34
2017 Q4 9.16M $25.9M -$498K $2.83 30
2017 Q3 9.32M $27.5M -$1.98M $2.95 30
2017 Q2 9.94M $31.3M -$1.13M $3.15 37
2017 Q1 10.1M $40.3M -$3.24M $4.00 36
2016 Q4 10.5M $80.8M +$2.07M $7.70 31
2016 Q3 9.93M $80.2M +$36.8M $8.10 30
2016 Q2 5.38M $32M -$2.51M $5.90 20
2016 Q1 5.69M $39.8M -$1.43M $6.99 24
2015 Q4 5.76M $46.3M +$2.27M $8.04 24
2015 Q3 5.35M $44.2M +$5.12M $8.26 24
2015 Q2 4.68M $53.9M +$3.17M $11.53 24
2015 Q1 4.45M $75.2M +$2.92M $16.86 23
2014 Q4 4.28M $83.1M +$74.1M $19.75 16